MedTrace Logo

Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

NCT04328831 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2023-10-10

No results posted yet for this study

Summary

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.

Conditions

  • Advanced Malignancies

Interventions

BIOLOGICAL

IBI322

Recombinant anti-human CD47/PD-L1 bispecific antibody injection

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2023-08-28
Completion
2023-08-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04328831 on ClinicalTrials.gov